Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.
about
Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis.Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in miceIdentification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screenTesting of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.Novel compounds active against Leishmania major.Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonensis infectionInterferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.Use of antimony in the treatment of leishmaniasis: current status and future directions.Construction of a Saccharomyces cerevisiae strain expressing the Leishmania major nucleoside hydrolase genePhosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.2-substituted quinoline alkaloids as potential antileishmanial drugsTreatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani.Pyrexia, pancytopenia and macrophage inclusions in an elderly woman.Leishmaniases of the New World: current concepts and implications for future researchThe antileishmanial effects of Lowsonia inermis and Cedrus libani on Leishmania major promastigotes: an in vitro study.Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light.Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexesAxenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.An axenic amastigote system for drug screeningAxenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog.Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania.Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.Leishmaniasis of the lip diagnosed by lymph node aspiration and treated with a combination of oral ketaconazole and intralesional sodium stibogluconate.Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).
P2860
Q24535789-01802265-5491-400F-BF20-D9D34D745085Q24671899-C0A252AD-C7D6-408C-8395-02472941B6D2Q28471705-274B3E76-EF6A-409C-BACA-AE9B23E2B332Q30444062-869D52D2-ACCD-4F3D-A397-9E19B0006BECQ30807168-3D81F299-55D9-476D-9EBD-ABB09E90CA9CQ33394175-A919C77A-D65D-4BF6-AD17-ECD101C1EDC3Q33565239-AD59B5B1-FCEB-459B-B19D-E665EA7BB244Q33614706-FA72D9F4-851E-484E-A3C3-3B3009617FCFQ34207978-9724C302-D883-470D-ABFE-C4BB5EE83D2CQ35007235-33222779-4305-47E5-977B-8021A3418F42Q35377767-D7CFC340-9CF2-41D3-ADAB-8582DDB0D7B8Q35741614-F6606734-EA5B-4755-8425-0C7E4F9FD9A8Q35764349-9B8C51B7-EF68-4D80-9691-67CF1B325BCDQ35812430-87DFC520-9AFF-4104-B98C-EDEA5BAF0522Q35817147-8982A72B-F4B8-48AC-A0DF-37274E5C7002Q35821639-B86F9051-693F-4898-8F0F-BF491149E91AQ36613400-4A0517C7-2A19-401D-BD37-0077452E17BAQ36640255-23C1A8DD-85A9-4E28-A334-839363E83E99Q38670961-CCC21362-71B9-4EEC-83F9-3839D9FC28F6Q39176904-57315BB7-3B0B-4CD8-84C6-A1F824E3F528Q39477783-4D1F3846-A052-4759-834C-D84DFF80D215Q39558272-7BD19825-C639-4725-BEA3-F81423D994C3Q39559595-26A035A5-25C0-4386-8FAD-9056A75D8547Q39779821-798675E4-A8D2-40B6-8533-A1474B37EFF4Q39783960-AC529D94-2DE3-45B3-ADE9-29559FB93931Q39784088-A6CC5AA8-CE3E-447A-A413-4CB0A13310D3Q39815819-FF5E7265-CA71-411A-A5C8-88433100FD1EQ39882545-DE75BF50-7AFC-4C87-8E38-A18317322438Q39883631-D76F8596-E0C2-4BC2-9A44-AC2CD80453A3Q40086831-B3F85993-1ABA-47DC-A608-4BCFA2EBDF04Q42746672-6F72F3DE-B906-41B7-A508-2A24C719DB55Q42947094-9AC12800-589D-4703-B55E-15010839A483
P2860
Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@en
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@nl
type
label
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@en
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@nl
prefLabel
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@en
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@nl
P1476
Chemotherapy for leishmaniasis ...... ficacy, and future strategies.
@en
P2093
P304
P577
1988-05-01T00:00:00Z